EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting RAS in pancreatic cancer

Fausto Petrelli, Lorenzo Dottorini, Alberto Zaniboni

Cancer · 2026

DOI: 10.1002/cncr.70640 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2026. Verfasst von Fausto Petrelli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Molecular Targeted Therapy, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and activating KRAS mutations occur in more than 90% of tumors. Direct RAS targeting has moved from proof of concept to randomized clinical benefit: in previously treated metastatic PDAC, daraxonrasib improved median overall survival, progression‐free survival, and objective response rate versus chemotherapy. Mutation‐selective G12C and G12D inhibitors, targeted degraders, and first‐line RAS (ON) combinations further broaden the landscape. Comprehensive germline and somatic profiling remains essential even with the availability of multi‐selective KRAS inhibitors. KRAS alleles differ biologically, drug activity against individual alleles is not yet fully characterized, and eligibility for clinical trials often depends on the specific genotype. In addition, KRAS wild‐type tumors may harbor actionable alterations, including gene fusions, amplifications, or mismatch‐repair deficiency. This review synthesizes RAS biology, molecular‐testing implications, clinical efficacy and toxicity data, and ongoing phase 2 and phase 3 trials. Priority questions include optimal sequencing, management of rash and mucositis, resistance, biomarker development, and integration into first‐line and curative‐intent therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalMolecular Targeted TherapyProto-Oncogene Proteins p21(ras)Antineoplastic AgentsHumansProto-Oncogene MasMutation

Stichwörter der Autor:innen

antineoplastic agentscarcinomamolecular‐targeted therapymutationpancreatic ductalprecision medicineproteolysisproto‐oncogene proteins p21(RAS)signal transduction

Substanzen

Proto-Oncogene MasMAS1 protein, humanProto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
  • Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.

Zitieren

APA

Petrelli, F., Dottorini, L., & Zaniboni, A. (2026). Targeting RAS in pancreatic cancer. Cancer. https://doi.org/10.1002/cncr.70640

Vancouver

Petrelli F, Dottorini L, Zaniboni A. Targeting RAS in pancreatic cancer. Cancer. 2026. doi:10.1002/cncr.70640

BibTeX
@article{Petrelli2026,
  author = {Petrelli, Fausto and Dottorini, Lorenzo and Zaniboni, Alberto},
  title = {Targeting RAS in pancreatic cancer},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70640}
}
Kostenlos starten →